Hester Biosciences Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year ended 31 March 2026, disclosing a total energy consumption of 53.09 Tera Joules and Scope 1 and Scope 2 greenhouse gas emissions of 8,626 metric tonnes of CO2 equivalent. The report, submitted to BSE Limited and National Stock Exchange of India Limited, highlights the company’s adherence to environmental and social governance standards, including zero safety incidents for the year and 100% sustainable sourcing from critical suppliers.

Environmental Performance

The company’s total energy consumption for FY26 stood at 53.09 Tera Joules, a decrease from 57.50 Tera Joules in the previous year. Energy from renewable sources accounted for 0.35 Tera Joules, while non-renewable sources contributed 52.74 Tera Joules. The energy intensity per rupee of turnover remained constant at 0.02. Total greenhouse gas emissions, comprising Scope 1 and Scope 2, totaled 8,626 metric tonnes of CO2 equivalent, down from 9,534 metric tonnes in FY25. The emission intensity per rupee of turnover improved to 2.95 from 3.33 in the prior year.

Water withdrawal decreased to 36,588 kilolitres in FY26 from 47,730 kilolitres in FY25, resulting in a water intensity per rupee of turnover of 12.52. The company reported total waste generation of 949.50 metric tonnes, with 99.53 metric tonnes recycled and 851.55 metric tonnes disposed of via incineration and landfilling. The company confirmed compliance with the Water Act, Air Act, and Environment Protection Act, holding a valid Consent to Operate from the Gujarat State Pollution Control Board.

Social and Governance Metrics

Hester Biosciences reported a workforce of 483 permanent employees and 321 workers as of 31 March 2026. Women constituted 9% of the permanent workforce and 3% of the total workers. The company achieved 100% coverage for health and accident insurance for permanent employees and workers. Return to work and retention rates for permanent employees and workers who took parental leave were both 100%. There were no reported cases of sexual harassment, discrimination, child labour, or forced labour during the year.

The company spent 1.16% of its total revenue on employee well-being measures, up from 1.08% in the previous year. It conducted training programmes covering health, safety, and skill upgradation for 100% of its employees and workers. The Board of Directors included two women, representing 20% of the Board.

Operational and Financial Disclosures

The company’s turnover for FY26 was INR 2,921.36 million, with exports contributing 11% to the total turnover. It serves markets across India and in over 35 countries internationally. The report identified material responsible business conduct issues including GHG emissions, waste management, water management, and talent retention, classifying them primarily as risks with potential negative financial implications.

The following table summarizes key environmental metrics for the financial year 2025-26:

The report confirms that the company has not conducted an independent assessment or evaluation of the environmental data by an external agency.

Hester Biosciences Limited reported a 99% increase in consolidated profit after tax to INR 574.84 million for the financial year ended 31 March 2026. Revenue from operations grew 7% to INR 3,325.99 million during the same period. On a standalone basis, profit after tax increased by 64% to INR 521.00 million, while revenue from operations rose 2% to INR 2,921.36 million.

The Poultry Healthcare division emerged as the primary growth driver, recording a 24% year-on-year increase in revenue. This performance was supported by deeper market penetration and sustained demand for the vaccine portfolio. A significant milestone during the year was the receipt of marketing and manufacturing licences for the H9N2 Avian Influenza vaccine, strengthening the company's biologicals portfolio. The Animal Healthcare segment faced challenges due to delays in government-led immunisation programmes, which impacted revenue in that division.

FY26 marked a significant step in infrastructure development with the capitalisation of the Fill-Finish facility and the BSL-3 facility. These investments are expected to enhance manufacturing capabilities and support future product development and market expansion. The company also undertook a partial divestment of its stake in Texas Lifesciences Private Limited, reducing its holding from 54.81% to 11%.

The Board of Directors has recommended a final dividend of INR 11 per equity share (110%) for the financial year 2025-26, subject to shareholder approval. The dividend pay-out ratio stands at 18% of standalone profits. The company’s net worth on a consolidated basis stood at INR 3,677.89 million as on 31 March 2026.

Financial Performance

The following table summarises the key financial metrics for the standalone and consolidated entities for the year ended 31 March 2026:

Operational Highlights

The company continued to strengthen its operational foundations during the year. The capitalisation of the Fill-Finish and BSL-3 facilities represents a significant step in enhancing manufacturing capabilities. These assets are designed to support future product development, manufacturing scale-up and market expansion. The repurposing of the BSL-3 facility for veterinary use further strengthens capabilities in high-biosecurity vaccine segments.

International operations remained stable, with growing traction in parts of Africa and steady performance in Tanzania. The company continued its involvement in the GALVmed-led VITAL programme, supporting expanded access to vaccines and their adoption for ruminant diseases across Africa.